Nanotechnology-based treatment for chemotherapy-resistant breast cancer

Abraham H. Abouzeid; Niravkumar R. Patel; Ilya M. Rachman; Sean Senn; Vladimir P. Torchilin

doi:10.1117/12.2064660

27 August 2014 Nanotechnology-based treatment for chemotherapy-resistant breast cancer

Abraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, Vladimir P. Torchilin

Proceedings Volume 9166, Biosensing and Nanomedicine VII; 916606 (2014) https://doi.org/10.1117/12.2064660
Event: SPIE NanoScience + Engineering, 2014, San Diego, California, United States

Abstract

Background: Treatment of metastatic cancer remains a formidable clinical challenge. Better therapeutic options with improved tissue penetration and tumor cell uptake are urgently needed. Targeted nanotherapy, for improved delivery, and combinatory drug administration aimed at inhibiting chemo-resistance may be the solution. Purpose: The study was performed to evaluate the therapeutic efficacy of polymeric PEG-PE micelles, co-loaded with curcumin (CUR) and doxorubicin (DOX), and targeted with anti-GLUT1 antibody (GLUT1) against MDA-MB-231 human breast adenocarcinoma cells both in vitro and in vivo. Methods: MDA-MB-231 DOX-resistant cells were treated with non-targeted and GLUT1-targeted CUR and DOX micelles as a single agent or in combination. Tumor cells were also inoculated in female nude mice. Established tumors were treated with the micellar formulations at a dose of 6 mg/kg CUR and 1 mg/kg DOX every 2 d for a total of 7 injections. Results: CUR+DOX-loaded micelles decorated with GLUT1 had a robust killing effect even at low doses of DOX in vitro. At the doses chosen, non-targeted CUR and CUR+DOX micelles did not exhibit significant tumor inhibition versus control. However, GLUT1-CUR and GLUT1-CUR+DOX micelles showed a significant tumor inhibition effect with an improvement in survival. Conclusion: We showed a dramatic improvement in efficacy between the non-targeted and GLUT1-targeted formulations both in vitro and in vivo. Also, importantly, the addition of CUR to the micelle, has restored sensitivity to DOX, with resultant tumor growth inhibition. Hence, we confirmed that GLUT1-CUR+DOX micelles are effective in vitro and in vivo and deserve further investigation.

Citation Download Citation

Abraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, and Vladimir P. Torchilin "Nanotechnology-based treatment for chemotherapy-resistant breast cancer", Proc. SPIE 9166, Biosensing and Nanomedicine VII, 916606 (27 August 2014); https://doi.org/10.1117/12.2064660

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
8 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Tumors

In vitro testing

Cancer

In vivo imaging

Polymers

Breast cancer

Glucose

Show All Keywords

Keywords/Phrases

Search In:

Publication Years